Iterum Therapeutics plc's ordinary shares will be delisted from The Nasdaq Capital Market. Trading of the company's ordinary shares will be suspended at the opening of business on April 1, 2026. The delisting follows the company's withdrawal of its appeal against a prior delisting determination due to failure to maintain a minimum bid price of $1.00 per share. The company filed a petition in the High Court in Ireland on March 27, 2026, to wind up the company. Due to limited cash resources and the ongoing winding up process, the company does not expect to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, or any other future filings with the SEC.